arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

Rezolute, Inc.

RZLT
$3.65 ▼ -0.31 (-7.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Rezolute, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $379.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -65.1% ↘
FCF / Share $-0.62 ↗
Trailing P/E —
Price / Book 3.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-77.59M
↓ -4.3% —
FCF / Share Free cash flow per share
$-0.62
↑ +31.6% —
Long-Term Debt Long-term obligations
$13.97M
↑ +127.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
10
Cash Quality ↓
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 66 quarters